Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY: JNJ )

157.02 +6.01 (+3.98%)
Streaming Delayed Price Updated: 2:24 PM EDT, Jul 17, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Johnson & Johnson

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
98 99 Next >
Johnson & Johnson Likely To Report Higher Q1 Earnings; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
Johnson & Johnson (NYSE: JNJ) is set to release earnings results for its first quarter before the opening bell on April 16, 2024. 
Via Benzinga
Bank of America, Morgan Stanley And 3 Stocks To Watch Heading Into Tuesday
With U.S. stock futures trading lower this morning on Tuesday, some of the stocks that may grab investor focus today are as follows: 
Via Benzinga
Fear & Greed Index Moves To 'Fear' Zone; S&P 500 Down Over 1%
The CNN Money Fear and Greed index showed a decline in the overall market sentiment, with the index moving to the "Fear" zone on Monday. U.S. stocks closed lower on Friday amid concerns over the... 
Via Benzinga
Topics Stocks
Exposures US Equities
J&J Braces For Q1 Earnings With Bearish Charts And Patent Cliffs In Play
Johnson & Johnson's Q1 earnings report on April 16 is expected to show $2.64 EPS and $21.4 billion in revenues. Technical analysis shows a bearish trend but analysts have a neutral rating with a... 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Medical Device Manufacture Integer To Gain From Expanding Pulsed Field Ablation Market, Earns Upgrade From BofA
BofA Securities' upgrades Integer, highlighting the growth potential of pulsed field ablation (PFA) in atrial fibrillation treatment. With projections of PFA sales skyrocketing from $100-200 million in... 
Via Benzinga
Topics Supply Chain
Exposures Supply Chain
A Closer Look at 9 Analyst Recommendations For Johnson & Johnson
Via Benzinga
Assessing Johnson &amp; Johnson's Performance Against Competitors In Pharmaceuticals Industry
Via Benzinga
The 3 Best Stocks to Buy to Survive the Coming S&P 500 Crash
You never know when a downturn will hit so it pays to prepare for the worst by buying these stocks before a market crash. 
Via InvestorPlace
Topics Stocks
Exposures US Equities
3 Quarterly Releases To Watch Next Week
Earnings season is always an exciting time for investors, with companies finally revealing what’s transpired behind closed doors. 
Via Talk Markets
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
The weekly Benzinga Stock Whisper Index highlights five stocks that saw increased interest from readers. Here are this week's stocks to watch. 
Via Benzinga
5 Dividend Kings That Yield More Than Vanguard's Top Value ETF
Despite a thriving bull market, some Dividend Kings still yield more than the Vanguard Value ETF's 2.4% payout. 
Via The Motley Fool
Topics ETFs
Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for April 2024
In a stock picker’s market, here are three biotech stocks analysts believe have a chance to outperform the market in 2024. 
Via InvestorPlace
All-Time High Flyers: 7 Stocks to Buy as the Market Peaks
These stocks to buy have enjoyed big rallies and the gains look likely to continue in coming months even if the market does peak. 
Via InvestorPlace
5 Things To Know In Investing This Week - The Shockwave Takeover Issue
The Shockwave offer that DKI predicted in December happened this week with Johnson & Johnson (NYSE: JNJ)agreeing to pay $335 per share in cash. DKI subscribers celebrated! The PMI came in  hot. Don’t... 
Via Benzinga
The $5 BILLION Reason Alpine Immune Sciences (ALPN) Stock Is Up 30% Today
Vertex hopes Alpine's drug can be tested on other conditions beyond the one entering Phase 3 trial for a kidney disease. 
Via InvestorPlace
Rare Disease-Focused Rallybio Inks Development Pact With Johnson & Johnson, Stock Shoots Higher
Rallybio partners with Johnson & Johnson to develop therapies targeting fetal and neonatal alloimmune thrombocytopenia, receiving $6.6 million investment. Phase 2 study for RLYB212 set for 2024. 
Via Benzinga
Nike Stock Jumps On Upgrade As Estimates 'Finally Look Achievable' Ahead Of Paris Olympics
Dow Jones giant Nike upgraded to buy. Estimates "finally look achievable" and the Paris Olympics should provide a boon. 
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Why Is Rallybio (RLYB) Stock Up 93% Today?
Rallybio stock is rocketing higher on Thursday with heavy trading of RLYB shares after announcing a collaboration with Johnson & Johnson. 
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
We're starting off Thursday with a breakdown of all the biggest pre-market stock movers traders will want to keep an eye on this morning! 
Via InvestorPlace
Joby’s $3.5B Air Taxi Dream Worth Less Than Trump’s Truth Social Nightmare?
Joby Aviation stock is down more than 20% in 2024. Despite the risk involved, aggressive investors are better served buying JOBY over TMTG. 
Via InvestorPlace
Topics Government
Exposures Political
Wall Street Favorites: 3 Dividend Stocks With Strong Buy Ratings for April 2024
These three dividend kings are among the most reliable dividend stocks, and each has at least one strong buy rating. 
Via InvestorPlace
7 Healthcare Stocks to Keep Your Portfolio in Tip-Top Shape
Although the market may be grumbling over certain issues, concerned investors can trust these healthcare stocks to deliver the goods. 
Via InvestorPlace
The Pharmaceutical Industry Finds Itself At A Historical Crossroads
Bristol Myers Squibb (NYSE: BMY), Merck & Co Inc (NYSE: MRK), Pfizer Inc (NYSE: PFE) and Johnson & Johnson(NYSE: 
Via Benzinga
If You Can Only Buy One Dividend Stock in April, It Better Be One of These 3 Names
The economy is performing pretty well, investing in these top dividend stocks to buy will guarantee good profits. 
Via InvestorPlace
Topics Economy
Exposures Economy
Does Johnson & Johnson's Latest Acquisition Make It a No-Brainer Buy?
The company is hoping to expand, but is there enough here to attract growth investors? 
Via The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
How's AT&T Handling Things?
We've also got a look at 3M's spinoff, gold prices, and the beef industry. 
Via The Motley Fool
3 Dividend Growth Stocks With Yields Above 3% That You Can Buy and Hold for the Next Decade
Income-seeking investors can look forward to steady payout raises from these pharma stocks. 
Via The Motley Fool
Johnson & Johnson's Carvykti Stands Ahead Of Bristol Myers' Rival Blood Cancer Therapy With FDA Approval For Wider Population
FDA approves Johnson & Johnson's Carvykti, a BCMA-targeted therapy for relapsed or refractory multiple myeloma patients, offering hope with increased manufacturing capacity and extended collaboration... 
Via Benzinga
Exposures Product Safety
Johnson & Johnson's $13B Shockwave Medical Deal Accelerates MedTech Strategy, Analyst Says
Johnson & Johnson acquires Shockwave Medical, bolstering its presence in cardiovascular intervention. The move marks a strategic shift, with around $30 billion invested in MedTech over 18 months. 
Via Benzinga
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
98 99 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.